Clinical Trials Directory

Trials / Unknown

UnknownNCT05410093

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Affiliated Hospital of Nantong University · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Resveratrol is a natural plant antitoxin widely found in grapes, mulberries, and other plants. Resveratrol mediates a variety of pharmacological effects, including antioxidant, immunomodulatory, anti-inflammatory, and anti-apoptotic, and plays a protective and therapeutic role in the development of several ROS-related diseases, including POI/POF.

Detailed description

The preliminary experiments of the investigators' group examined the gene expression in ovarian granulosa cells of POI patients and normal controls using high-throughput sequencing technology. The investigators found that the expression of NOX complex NCF1, NCF2, NCF4 and CYBB subunit genes were upregulated in ovarian granulosa cells of POI patients compared with normal controls, suggesting that the development of POI may be related to the NOX complex subunit gene and The development of POI may be related to the abnormal expression of genes and proteins of NOX complex subunits. Based on the results of previous experiments and available literature reports, investigators compared ovarian function, embryonic laboratory indices, pregnancy outcome and cellular level NOX/ROS/oxidative stress changes of POI patients in the RES-treated and non-RES-treated groups by collecting blood and ovarian granulosa cell samples to analyze the effects, mechanisms of action and specific RES application in antioxidant therapy for POI NOX subunit targets to provide a reliable scientific basis for the clinical treatment of POI by RES.

Conditions

Interventions

TypeNameDescription
DRUGResveratrolTake Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
DRUGVitamin ETake vitamin E at a dose of 100 mg per day for three months

Timeline

Start date
2022-02-01
Primary completion
2024-07-31
Completion
2024-07-31
First posted
2022-06-08
Last updated
2022-06-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05410093. Inclusion in this directory is not an endorsement.